OR WAIT 15 SECS
The new mAb manufacturing facility in Switzerland will supply material for clinical development.
Glenmark Pharmaceuticals, India, has opened a new cGMP-compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. This manufacturing facility supplements Glenmark's existing in-house discovery and development capabilities and will supply material for clinical development.
Glenmark Pharmaceuticals' Swiss research center has in-house capabilities and infrastructure for conducting antibody discovery, cell-line development, in-vitro testing and characterization of antibodies, process development, and analytical research. The new manufacturing facility supplements the research and development capabilities and will facilitate production of clinical grade material. The manufacturing facility has been designed for use of single-use bioreactor systems and also houses a suite for manufacturing cell banks.
Source: Glenmark Pharmaceuticals